

Main Office : Loc. Bellaria, 35 - 53018 Sovicille (Siena) Italy
Tel. (+39) 0577 17816 – Fax (+39) 0577 1781680

Registered Office : La Lizza, 7 – 53100 Siena (Italy)
e.mail: info@philogen.it – web site: www.philogen.it
VAT ID NO. IT 00893990523

Philogen
innovating targeting

Philogen: new data on clinical products presented at ASCO

Philogen announces that it will have presentations by its Principal Investigators at the 2011 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, June 3rd-7th. Accepted abstracts include:

1) Darleukin (L19-IL2) in Metastatic Melanoma

- **A dose confirmation and signal generating study of the immunocytokine L19-IL2 in combination with dacarbazine in patients with metastatic melanoma**

Presenter: Dr. Thomas Eigentler, University of Tübingen, Germany.

Abstract #2531 presented on Saturday 4th June between 08:00 and 12:00 in room S403.

This poster has been selected for poster discussion #80383 at 12:00 on Saturday 4th June in room S406.

2) Teleukin (F16-IL2) in Solid Tumors

- **Combination of the immunocytokine F16-IL2 with doxorubicin or paclitaxel in patients with solid tumors: results from two phase Ib trials**

Presenter: Dr. Filippo De Braud, European Institute of Oncology, Milan, Italy.

Abstract #2595 presented on Monday 6th June between 08:00 and 12:00 in Hall A.

3) Tenarad (F16-I¹³¹) in Hodgkin's Disease

- **Preliminary evaluation of radioimmunotherapy with Tenarad, a I¹³¹ labeled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's disease (HD)**

Presenter: Dr. Luigi Aloj, Department of Nuclear Medicine and Radionuclide Therapy, Istituto Nazionale Tumori, Fondazione Pascale, Naples, Italy.

Abstract #8063 presented on Monday 6th June between 13:00 and 17:00 in Hall A.

4) Radretumab (L19-I¹³¹) in Brain Metastases from solid cancer

- **Preliminary evaluation of radioimmunotherapy with I¹³¹ labeled small immunoprotein targeted against the extra domain B of fibronectin in combination with whole brain radiation in patients with multiple brain metastases from solid tumors.**

Contributor: Dr. Secondo Lastoria, Department of Nuclear Medicine and Radionuclide Therapy, Istituto nazionale Tumori, Fondazione Pascale, Naples, Italy.

Abstract e12502, available as an abstract contribution.

About Philogen's drugs in advanced clinical development:

Philogen has seven armed antibodies in clinical development. The presentations at ASCO cover four of the products within Philogen's pipeline.

Phase II data on one of Philogen's lead compounds, darleukin (L19-IL2), confirms that this immunocytokine can be safely and repeatedly administered to patients with metastatic melanoma and shows very promising signs of clinical activity, improving the life expectancy well above that predicted for pre-treated patients. This data has given Philogen great confidence in the potential of this drug, and we are currently undertaking a controlled, randomized Phase II study involving 90 patients to further corroborate the clinical data.

The update on teleukin (F16-IL2) covers two Phase Ib studies in combination with paclitaxel or doxorubicin that have recently been completed and evaluated. These studies demonstrated that this compound can be safely and repeatedly administered in combination with full-dose chemotherapy to advanced solid cancer patients. Moreover, teleukin showed early signs of clinical activity, and as a consequence is now being tested in combination regimens in Phase II breast cancer trials.

One of Philogen's radio-labeled products, tenarad (F16-I¹³¹) showed in a Phase I/II trial in patients with progressive Hodgkin's lymphoma refractory to conventional treatment that tenarad had acceptable toxicity and resulted in objective responses in many patients. Further Phase II trials are in progress.

Radretumab (L19-I¹³¹) is a Philogen product in Phase II clinical development as an add-on to whole brain radiation for the treatment of patients with brain metastases from solid cancer. The clinical trial reported here have shown that in this patient population with a very poor prognosis, the treatment is well tolerated and provides acceptable levels of toxicity. Radretumab is currently in Phase II studies assessing the therapeutic efficacy of this armed antibody.